8月7日，微创医疗(00853)盘中上涨2.33%，截至10:35，报14.08元/股，成交3.38亿元。 本文源自：金融界 微创医疗科学有限公司是一家跨国企业集团，专注于心血管、脑血管、神经系统、骨科学等多个领域的 创新医疗技术，致力于提供普惠化的医疗解决方案。公司在全球多个地区设有创新中心和生产基地，产 品已进入全球超过100个国家和地区，帮助挽救和延长生命。 截至2024年年报，微创医疗营业总收入74.12亿元、净利润-15.39亿元。 作者：行情君 ...

截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 微創醫療科學有限公司 呈交日期: 2025年8月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00853 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 5,000,000,000 | USD | | 0.00001 | USD | | 50,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 5,000,000,000 | USD | | 0.00001 | USD | | 50,000 | 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 本月底法定/註冊股本總額 ...

Core Insights - The article highlights significant declines in the prices of certain Chinese offshore bonds, particularly those issued by Sunac China Holdings, which saw a daily drop of 36.52% for its USD bond [2][4] Group 1: Bond Performance - The largest decline in the day was observed in the bond SUNSHI 7.5% 4/15/24 issued by Sunac China Holdings, which fell to a price of 0.18 [2] - Other notable bonds include SUNSHI 10.25% 9/15/22, which decreased to 0.19, and JOYY 1.375% 6/15/26, which is priced at 69.63 [4] - The bond prices of several other companies, such as China Aoyuan Group and Shimao Group, also reflect varying levels of performance, with Shimao's bonds priced at 4.24 [4] Group 2: Market Context - The data is sourced from the China Economic Society's enterprise foreign debt risk monitoring system, indicating a broader trend in the offshore bond market [2][4] - The report is updated as of 2025, suggesting ongoing monitoring of these financial instruments [2][4]

本文源自：金融界 作者：行情君 截至2024年年报，微创医疗营业总收入74.12亿元、净利润-15.39亿元。 8月5日，微创医疗(00853)盘中上涨2.04%，截至13:41，报13.52元/股，成交5.84亿元。 微创医疗科学有限公司是一家跨国企业集团，专注于心血管、脑血管、神经系统、骨科学等多个领域的 创新医疗技术，致力于提供普惠化的医疗解决方案。公司在全球多个地区设有创新中心和生产基地，产 品已进入全球超过100个国家和地区，帮助挽救和延长生命。 ...

Summary of Key Points from Medical Device Industry and Companies Industry Overview - The medical device sector has faced challenges due to centralized procurement and anti-corruption measures, leading to concerns about earnings certainty. However, with policy optimization and growth in international business, opportunities are increasing within the sector [1][2] - The medical device index has rebounded by 12% since the beginning of the year, following a period of decline due to significant events and policy factors [2] Company Performance and Outlook - **Mindray Medical**: Experienced revenue and profit pressure due to delayed domestic equipment tenders, but is expected to see a performance turnaround in Q3. The company has significant international growth potential [3][11] - **MicroPort Medical**: Currently has a low valuation, with a projected valuation of only 11 times earnings next year. The company is expected to benefit from the approval of its coronary stent application in the U.S. and potential domestic approval [5] - **Sino Medical**: Recent approval of its intracranial self-expanding drug stent is expected to drive growth, with strong clinical results anticipated to facilitate commercialization [19] - **HuiTai Medical**: In the electrophysiology sector, the company is expected to see rapid growth due to innovative products like PFA ablation catheters, which are anticipated to gain market traction [14][13] Sector-Specific Insights - **High-Value Consumables**: The sector is seeing valuation recovery and improved earnings certainty due to policy optimization. Surgical volumes are expected to grow steadily, with specific segments like electrophysiology and peripheral nerve intervention showing high growth potential [7][8] - **IVD Sector**: The IVD industry is facing challenges from price adjustments in testing services, but companies with strong innovation capabilities and international expansion potential are still expected to grow [9][28] Investment Opportunities - Companies like **Xinmai Medical** and **Nanwei Medical** have shown significant stock price increases, with some companies in the medical device sector experiencing substantial gains [4] - Low-valuation growth potential stocks such as **Chunli Medical** and **Yingke Medical** have seen price increases of up to 60% since Q2 [4][5] - The orthopedic sector is stabilizing, with companies like **Chunli** and **Aikang** showing potential for international market expansion [12] Future Trends - The medical device sector is expected to see a performance turnaround starting in Q3, driven by improved tender data and reduced channel inventory pressure [6][10] - The overall medical industry is projected to face volume and price pressures in the first half of 2025, but improvements are expected in the second half, potentially leading to a growth inflection point by year-end [10] Conclusion - The medical device industry is on the cusp of recovery, with several companies poised for growth due to policy changes and international expansion. Investors are encouraged to focus on undervalued companies with strong growth potential, particularly in high-value consumables and innovative medical technologies [29]

截至2024年年报，微创医疗营业总收入74.12亿元、净利润-15.39亿元。 本文源自：金融界 作者：行情君 8月5日，微创医疗(00853)盘中下跌2.94%，截至10:06，报12.86元/股，成交3.01亿元。 微创医疗科学有限公司是一家跨国企业集团，专注于心血管、脑血管、神经系统、骨科学等多个领域的 创新医疗技术，致力于提供普惠化的医疗解决方案。公司在全球多个地区设有创新中心和生产基地，产 品已进入全球超过100个国家和地区，帮助挽救和延长生命。 ...

Group 1 - The core viewpoint of the articles highlights the increasing trend of state-owned enterprises (SOEs) in the Yangtze River Delta region engaging in mergers and acquisitions (M&A) to promote local industrial integration and development, shifting from financial investments to deep industrial integration [1][2][3] - In 2025, there have been 17 cases of SOEs directly or indirectly participating in the acquisition of A-share listed companies, with over half of the targets in the machinery, electronics, petrochemicals, and computer sectors, indicating a focus on regional resource optimization and industrial collaboration [1][2] - The current wave of M&A is driven by local governments' strategies to enhance industrial clusters, aiming to strengthen, supplement, and extend the industrial chains [1][2][3] Group 2 - SOEs are utilizing specialized M&A funds to strategically invest in or take control of "chain leader" companies, thereby enhancing local industries and releasing synergistic effects [2][3] - A notable example is the strategic investment by a Shanghai biomedical M&A fund in MicroPort Medical, which aims to support the development of the biomedical sector and attract talent and technological breakthroughs [2][3] - The trend of cross-provincial acquisitions is evident, with SOEs from Jiangsu, Anhui, and Zhejiang acquiring companies in Guangdong and Chongqing, showcasing an upgraded model of "capital attraction + industrial attraction" [5][6] Group 3 - The integration of high-quality scientific and technological assets into SOEs through M&A not only facilitates strategic upgrades for these companies but also optimizes the industrial layout for local SOEs [6] - Data indicates that most of the listed companies acquired by SOEs in the Yangtze River Delta this year have market values below 10 billion yuan, with 10 companies valued under 5 billion yuan and 7 between 5 billion and 10 billion yuan [5][7] - The approach of using M&A as a tool for local industrial development serves as a model for other regions, promoting resource integration and enhancing local industrial chains [3][5]

因此，于2025年8月4日，4355万股换股股份(占紧接发行换股股份前全部已发行股份约2.34%及占经发行 换股股份扩大后全部已发行股份约2.29%)已根据可换股贷款的条款及条件配发予相关贷款人。 微创医疗(00853)发布公告，本公司近期接获贷款人发出的若干换股通知，要求行使可换股贷款附带的 换股权，以按每股换股股份7.46港元的换股价将本金总额4150万美元(相当于3.25亿港元)的部分贷款转 换为4355万股换股股份。 ...

因此，于2025年8月4日，4355万股换股股份(占紧接发行换股股份前全部已发行股份约 2.34%及占经发 行换股股份扩大后全部已发行股份约2.29%)已根据可换股贷款的条款及条件配发予相关贷款人。 智通财经APP讯，微创医疗(00853)发布公告，本公司近期接获贷款人发出的若干换股通知，要求行使可 换股贷款附带的换股权，以按每股换股股份7.46港元的换股价将本金总额4150万美元(相当于3.25亿港 元)的部分贷款转换为 4355万股换股股份。 ...

因此，于2025年8月4日，43,549,965股换股股份（占紧接发行换股股份前全部已发行股份约2.34%及占 经发行换股股份扩大后全部已发行股份约2.29%）已根据可换股贷款的条款及条件配发予相关贷款人。 格隆汇8月4日丨微创医疗(00853.HK)公告，公司近期接获贷款人发出的若干换股通知，要求行使可换股 贷款附带的换股权，以按每股换股股份7.46港元的换股价将本金总额41,500,000美元的部分贷款转换为 43,549,965股换股股份。 ...